| Parameter | Description | Baseline† or RR | Lower limit (95% CrI) | Upper limit (95% CrI) |
|---|---|---|---|---|
| Treatment efficacy (sustained virologic response) | ||||
| Genotype 1 | ||||
| Noncirrhosis | ||||
| Reference baseline PR48 | Pegylated interferon + ribavirin for 48 wk | 0.4913† | 0.4359 | 0.5456 |
| SOF12 + LDV12 | Sofosbuvir + ledipasvir for 12 wk | 1.978 | 1.78 | 2.225 |
| PAR/RIT12 + OMB12 + DAS12 | Paritaprevir-ritonavir + ombitasvir + dasabuvir for 12 wk | 1.932 | 1.337 | 2.211 |
| Cirrhosis | ||||
| Reference baseline PR48 | 0.3898† | 0.3099 | 0.475 | |
| SOF12 + LDV12 | 2.442 | 1.956 | 3.091 | |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | Paritaprevir-ritonavir + ombitasvir + dasabuvir + ribavirin for 12 wk | 2.416 | 1.942 | 3.057 |
| Genotype 2 | ||||
| Noncirrhosis | ||||
| SOF12 + RBV12 | Sofosbuvir + ribavirin for 12 wk | 1.16 | 1.083 | 1.244 |
| Reference baseline PR24 | Pegylated interferon + ribavirin for 24 wk | 0.8191† | 0.7687 | 0.8619 |
| Cirrhosis | ||||
| SOF12 + RBV12 | 1.375 | 1.026 | 1.791 | |
| Reference baseline PR24 | 0.6209† | 0.4966 | 0.7344 | |
| Genotype 3 | ||||
| Noncirrhosis | ||||
| Reference baseline PR48 | 0.7051† | 0.6393 | 0.765 | |
| SOF24 + RBV24 | Sofosbuvir + ribavirin for 24 wk | 1.318 | 1.177 | 1.47 |
| DCV12 + SOF12 | Daclatasvir + sofosbuvir for 12 wk | 1.375 | 1.233 | 1.525 |
| Cirrhosis | ||||
| Reference baseline PR48 | 0.6021† | 0.5584 | 0.6441 | |
| SOF24 + RBV24 | 1.509 | 1.142 | 1.702 | |
| Genotypes 4-6 | ||||
| PR48 | 0.65 | 0.57 | 0.71 | |
| Adverse events (treatment-naive people) | ||||
| Depression | ||||
| Reference baseline PR48 | 0.1381† | 0.11 | 0.1683 | |
| SOF12 + RBV12 | 0.2861 | 0.07992 | 0.958 | |
| SOF24 + RBV24 | 0.7751 | 0.165 | 3.181 | |
| SOF12 + LDV12 | 0.01888 | 0.002205 | 0.09946 | |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | 0.4174 | 0.08099 | 1.534 | |
| PR24 | 0.756 | 0.1592 | 2.831 | |
| Anemia | ||||
| Reference baseline PR48 | 0.2136† | 0.1838 | 0.2459 | |
| SOF12 + RBV12 | 0.6949 | 0.3601 | 1.309 | |
| SOF24 + RBV24 | 1.263 | 0.4806 | 2.528 | |
| SOF12 + LDV12 | 0.05568 | 0.02193 | 0.1322 | |
| PAR/RIT12 + OMB12 + DAS12 | 0.3454 | 0.1431 | 0.7469 | |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | 0.3826 | 0.1549 | 0.8366 | |
| PR24 | 0.9708 | 0.4121 | 2.065 | |
| Rash | ||||
| Reference baseline PR48 | 0.1828† | 0.1465 | 0.2186 | |
| SOF12 + RBV12 | 0.5244 | 0.167 | 1.598 | |
| SOF24 + RBV24 | 0.7655 | 0.07902 | 2.721 | |
| SOF12 + LDV12 | 0.2626 | 0.1415 | 0.4803 | |
| PAR/RIT12 + OMB12 + DAS12 | 0.2194 | 0.08837 | 0.525 | |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | 0.7214 | 0.3777 | 1.301 | |
| PR24 | 1.03 | 0.3068 | 2.839 | |
| Treatment discontinuation rate | Base estimate | Lower limit (95% CI) | Upper limit (95% CI) | |
| PR48 | 0.173 | 0.096 | 0.292 | |
| SOF12 + RBV12 | 0.089 | 0.038 | 0.194 | |
| SOF24 + RBV24 | 0.054 | 0.015 | 0.18 | |
| SOF12 + LDV12 | 0.044 | 0.023 | 0.083 | |
| PAR/RIT12 + OMB12 + DAS12 | 0.005 | 0.001 | 0.033 | |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | 0.015 | 0.003 | 0.071 |
Note: CI = confidence interval, CrI = credible interval, RR = relative risk.
*Source: references 9 and 11, with the exception of genotypes 4-6 (references 12-14).
†Baseline probability.